Abiopharma

🔍 Miller Lisa K (Executive)

Company: LifeStance Health Group, Inc. (LFST)

Report Date: 2026-03-09

Detailed Transactions and Holdings:

• Sold 14,766 shares of Common Stock at $6.91 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: false | shares_owned_after: 315,811.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 26,836 shares of Common Stock (Direct)
  Date: 2026-03-09 | Code: A | equity_swap_involved: false | shares_owned_after: 342,647.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 13,446 shares of Common Stock at $6.91 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: false | shares_owned_after: 329,201.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the net settlement of restricted stock units ("RSUs") that vested on March 9, 2026. The shares withheld represent a reduction of shares issued to the Reporting Person upon settlement of vested RSUs and do not constitute any open-market sale.
• F2: Represents performance-based restricted stock units ("PSUs") previously granted to the Reporting Person on March 6, 2025, which vested on March 9, 2026.
• F3: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the net settlement of PSUs that vested on March 9, 2026. The shares withheld represent a reduction of shares issued to the Reporting Person upon settlement of vested PSUs and do not constitute any open-market sale.